Company intelligence / Profile preview

DotLab

Ownership: Private
Development stage: Other

Overview

DotLab has developed and commercialized the first-of-its-kind blood test, called DotEndo, which aids in the diagnosis of active endometriosis. This non-invasive diagnostic addresses a significant unmet need by reducing the average time to diagnosis from up to ten years down to a much shorter period. The company partners with global pharmaceutical research clients and leverages novel biomarkers and machine learning for clinical innovation[2][3][4].

Therapeutic areas: Women's Health
Modalities: Diagnostic test (blood-based biomarker assay)
Industry: Protein Biomarker Diagnostics

Partnerships

Top-tier global pharmaceutical research clients

Beyond the preview

Go deeper on DotLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DotLab.

Explore the full profile